GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Source: Newsfilter
- FDA Approval Milestone: The FDA's November approval of the first bispecific antibody combination for second-line blood cancer treatment marks a significant shift from traditional chemotherapy, which is expected to enhance market performance for companies like GT Biopharma.
- Clinical Trial Advancement: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients are receiving a dosing of 10μg/kg/day, indicating potential efficacy in patients with relapsed blood cancers, which could open new market opportunities for the company.
- Safety Validation: Six patients enrolled in Cohorts 1, 2, and 3 have successfully completed GTB-3650 treatment, establishing the therapy's safety profile across escalating doses, laying the groundwork for subsequent trials at higher doses.
- Future Outlook: The company anticipates sharing the next trial update in Q1 2026, and as dosing increases, clinical efficacy is expected to improve further, potentially attracting more investor interest.
GTBP
$0.805+Infinity%1D
Analyst Views on GTBP
Wall Street analysts forecast GTBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GTBP is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.774
Low
8.00
Averages
8.00
High
8.00
Current: 0.774
Low
8.00
Averages
8.00
High
8.00
About GTBP
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
